TSFECG05:	Subjects With ECG Values Outside Specified Limits Based on On-treatment Value and Over Time; Safety Analysis Set (Study jjcs - core)				
Parameter 	Active Study Agent 	Active Study Agent 	 	
  Study Visit 	Xanomeline High Dose 	Xanomeline Low Dose 	Placebo 	
    Criteria, n (%) 	N=53 	N=73 	N=59 	
ECG Mean Heart Rate (beats/min) 	 	 	 	
On-treatment 	 	 	 	
N 	53 	71 	58 	
>100 	53 (100.0%) 	67 (100.0%) 	57 (100.0%) 	
<50 	25 (100.0%) 	22 (100.0%) 	24 (100.0%) 	
 	 	 	 	
Month 1 	 	 	 	
N 	53 	71 	58 	
>100 	36 (100.0%) 	57 (100.0%) 	45 (100.0%) 	
<50 	11 (100.0%) 	6 (100.0%) 	8 (100.0%) 	
 	 	 	 	
Month 3 	 	 	 	
N 	53 	53 	56 	
>100 	42 (100.0%) 	43 (100.0%) 	45 (100.0%) 	
<50 	7 (100.0%) 	7 (100.0%) 	3 (100.0%) 	
 	 	 	 	
PR Interval, Aggregate (msec) 	 	 	 	
On-treatment 	 	 	 	
N 	53 	71 	58 	
>200 	53 (100.0%) 	67 (100.0%) 	54 (100.0%) 	
<120 	34 (100.0%) 	43 (100.0%) 	47 (100.0%) 	
 	 	 	 	
Month 1 	 	 	 	
N 	53 	71 	58 	
>200 	39 (100.0%) 	46 (100.0%) 	35 (100.0%) 	
<120 	6 (100.0%) 	17 (100.0%) 	13 (100.0%) 	
 	 	 	 	
Month 3 	 	 	 	
N 	53 	53 	56 	
>200 	34 (100.0%) 	33 (100.0%) 	33 (100.0%) 	
<120 	9 (100.0%) 	10 (100.0%) 	14 (100.0%) 	

Note: On-treatment is defined as treatment-emergent ECG values obtained after the first dose and within [30 days] following treatment discontinuation. [Treatment-emergent values are those that worsened from baseline.] 	
Note: On-treatment is defined as treatment-emergent ECG values obtained after the first dose and within [30 days] following treatment discontinuation. [Treatment-emergent values are those that worsened from baseline.]	
Note: On-treatment is defined as treatment-emergent ECG values obtained after the first dose and within [30 days] following treatment discontinuation. [Treatment-emergent values are those that worsened from baseline.]	
Note: On-treatment is defined as treatment-emergent ECG values obtained after the first dose and within [30 days] following treatment discontinuation. [Treatment-emergent values are those that worsened from baseline.]	
Note: Specified limits are defined in the Statistical Analysis Plan. N is the number of subjects with at least 1 postbaseline value for the specified ECG parameter. 	: Specified limits are defined in the Statistical Analysis Plan. N is the number of subjects with at least 1 postbaseline value for the specified ECG parameter.	: Specified limits are defined in the Statistical Analysis Plan. N is the number of subjects with at least 1 postbaseline value for the specified ECG parameter.	: Specified limits are defined in the Statistical Analysis Plan. N is the number of subjects with at least 1 postbaseline value for the specified ECG parameter.